Capromorelin

Brand names: Entyce · Active ingredient: Capromorelin Tartrate

In short: ENTYCE (capromorelin oral solution) is indicated for appetite stimulation in dogs.

LabelElanco US Inc.
Label updatedDec 18, 2025

What is Capromorelin used for?

ENTYCE (capromorelin oral solution) is indicated for appetite stimulation in dogs.

âš  Boxed warning (FDA's strongest warning)

User Safety Warnings:

Not for use in humans. Keep this drug, including used syringes, out of reach of children. Wash hands immediately after use as this product may be dermally absorbed. Consult a physician in case of accidental ingestion by humans. To obtain a Safety Data Sheet(s), contact Elanco US Inc. at 1-888-545-5973.

For use in dogs only.

Animal Safety Warnings:

Keep ENTYCE in a secure location out of reach of dogs, cats, and other animals to prevent accidental ingestion or overdose.

Capromorelin dosage

Administer ENTYCE orally at a dose of 3 mg/kg (1.4 mg/lb) body weight once daily.

To administer ENTYCE follow the written instructions below and see illustrations 1 through 4 for administration steps.

1.Gently shake the bottle.

2.Remove the bottle cap and insert the provided dosing syringe firmly into the opening of the bottle.

3.Turn the bottle upside down and withdraw the appropriate volume of solution. Return the bottle to the upright position before removing the syringe, and replace the cap.

4.Administer the solution with the syringe into the dog's mouth.

Rinse the syringe and plunger with water between treatment doses. Leave the syringe and plunger apart to dry. Wash hands immediately after use.

The effectiveness of ENTYCE has not been evaluated beyond 4 days of treatment in the clinical field study .

Warnings & precautions

Do not take this medicine if: ENTYCE should not be used in dogs that have a hypersensitivity to capromorelin.

Use with caution in dogs with hepatic dysfunction. ENTYCE is metabolized by CYP3A4 and CYP3A5 enzymes .

Use with caution in dogs with renal insufficiency. ENTYCE is excreted approximately 37% in urine and 62% in feces .

Use with caution in dogs that may have cardiac disease or severe dehydration. ENTYCE can cause transient decreases in heart rate and blood pressure following dose administration. Some dogs may exhibit clinical signs of bradycardia or hypotension following administration of ENTYCE .

Use with caution in dogs with diabetes mellitus as hyperglycemia has been reported following administration of ENTYCE .

The safe use of ENTYCE has not been evaluated in dogs used for breeding or pregnant or lactating bitches.

Capromorelin side effects

In a controlled field study, 244 dogs were evaluated for safety when administered either ENTYCE or a vehicle control (solution minus capromorelin) at a dose of 3 mg/kg once daily for 4 days. Enrolled dogs had a reduced or absent appetite for a minimum of 2 days prior to day 0 and had various medical conditions: arthritis (40); gastrointestinal disease (24); allergy (22); dental disease (22); cardiovascular disease (16); renal disease (13); and others. Some dogs may have experienced more than one of the adverse reactions during the study.

The following adverse reactions were observed:

Adverse Reactions | ENTYCE (n = 171)

n (%) | Vehicle Control (n = 73)

n (%)

GASTROINTESTINAL

Diarrhea | 12 (7.0 %) | 5 (6.8 %)

Vomiting | 11 (6.4 %) | 4 (5.5 %)

Hypersalivation | 4 (2.3 %) | 0 (0.0 %)

Abdominal discomfort | 2 (1.2 %) | 0 (0.0 %)

Flatulence | 2 (1.2 %) | 0 (0.0 %)

Nausea | 2 (1.2 %) | 0 (0.0 %)

CLINICAL PATHOLOGY

Elevated blood urea nitrogen | 7 (4.1 %) | 2 (2.7 %)

Elevated phosphorus | 4 (2.3 %) | 1 (1.4 %)

Elevated creatinine | 1 (0.6 %) | 1 (1.4 %)

OTHER

Polydipsia | 7 (4.1 %) | 1 (1.4 %)

Lethargy/depression | 2 (1.2 %) | 0 (0.0 %)

The following adverse reactions were reported in < 1% of dogs administered ENTYCE: hyperactivity, increase fecal volume, increase gut sounds, and polyuria.

Post-Approval Experience (2025):

The following adverse events are based on post-approval adverse drug experience reporting for ENTYCE. Not all adverse events are reported to FDA/CVM. …

About this medicine

ENTYCE (capromorelin oral solution) is a selective ghrelin receptor agonist that binds to receptors and affects signaling in the hypothalamus to cause appetite stimulation and binds to the growth hormone secretagogue receptor in the pituitary gland to increase growth hormone secretion. The empirical formula is C28H35N5O4·C4H6O6 and the molecular weight 655.70. The chemical name is 2-amino-N-[2-(3aR-benzyl-2-methyl-3-oxo-2,3,3a,4,6,7-hexahydro-pyrazolo[4,3-c]pyridin-5-yl)1R-benzyloxymethyl-2-oxo-ethyl]-isobutyramide L-tartrate.

The chemical structure of capromorelin tartrate is:

How it works: Following oral administration of ENTYCE at a dose of 3 mg/kg to 12 Beagle dogs, absorption of capromorelin was rapid with the maximum concentration (Cmax) reached within 0.83 hr (Tmax). After Cmax, the plasma concentrations declined mono-exponentially with a short terminal half-life (T½) of approximately 1.19 hrs. There were no gender differences in capromorelin pharmacokinetics.

Disclaimer: This page is for general information only and is not medical advice. It is a condensed summary of the official FDA-approved label — it does not replace the full prescribing information or the advice of your doctor or pharmacist. Always follow your prescriber's instructions and read the medication guide that comes with your medicine.

Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID 0a403b74-72be-4f90-a069-d747caea1247. Read the full official label on DailyMed.